Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||axicabtagene ciloleucel + Lenzilumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Lenzilumab||KB003|KB 003||Lenzilumab (KB003) is an antibody that targets granulocyte macrophage colony-stimulating factor (GM-CSF), potentially resulting in increased apoptosis and decreased proliferation of tumor cells (PMID: 32294158).|
|axicabtagene ciloleucel||Yescarta||KTE-C19 CAR|KTE-C19||Yescarta (axicabtagene ciloleucel) is an immunotherapy consisted of peripheral T-lymphocytes engineered to express a chimeric antigen receptor targeting CD19, CD28 and CD3zeta, resulting in immunostimulating and antineoplastic activities (PMID: 32401634). Yescarta (axicabtagene ciloleucel) is FDA approved for adult patients with large B-cell lymphoma who is refractory or relapsed on first-line chemoimmunotherapy or have received two or more lines of therapies, including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma, and for adult patients with relapsed or refractory follicular lymphoma who have received two or more lines of therapies, but is not indicated for patients with primary central nervous system lymphoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04314843||Phase Ib/II||axicabtagene ciloleucel + Lenzilumab Cyclophosphamide + Fludarabine||Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma (ZUMA-19)||Terminated||USA||0|